Myriad Genetics (MYGN) Depreciation & Amortization (CF) (2009 - 2026)

Myriad Genetics has disclosed Depreciation & Amortization (CF) across 18 years of filings, most recently posting $12.5 million for Q1 2026.

• In Q1 2026, Depreciation & Amortization (CF) fell 13.19% year-over-year to $12.5 million; the TTM figure through Mar 2026 stood at $51.8 million (down 13.52% YoY), while the FY2025 annual figure was $53.7 million, down 12.25% from the prior year.
• Depreciation & Amortization (CF) fell to $12.5 million in Q1 2026, from $12.6 million in the prior quarter.
• Over the last five years, Depreciation & Amortization (CF) for MYGN reached as high as $19.4 million in Q1 2023 and fell as low as $12.5 million in Q1 2026.
• The 5-year median for Depreciation & Amortization (CF) is $14.1 million (2023), against an average of $14.2 million.
• Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) declined 29.35% — and 2023, when it jumped 49.23%.
• A 5-year view of Depreciation & Amortization (CF) shows it stood at $13.7 million in 2022, then increased by 10.22% to $15.1 million in 2023, then slipped by 1.99% to $14.8 million in 2024, then fell by 14.86% to $12.6 million in 2025, then decreased by 0.79% to $12.5 million in 2026.
• According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $12.5 million, $12.6 million, and $12.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.